<DOC>
	<DOC>NCT01904058</DOC>
	<brief_summary>The study is a randomized, double-blind, placebo-controlled, multicenter study. It is a 13-week Phase 2 study in adults with primary biliary cirrhosis designed to compare the effect of daily dosing with UDCA in combination with LUM001 or placebo.</brief_summary>
	<brief_title>Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1. Diagnosis of Primary Biliary Cirrhosis 2. Moderate to severe pruritus 3. Taking ursodeoxycholic acid (UDCA) for at least 6 months, or unable to tolerate UDCA 4. Ability to understand and willingness to sign informed consent prior to initiation of any study procedures 1. History or presence of other concomitant significant liver disease 2. Liver transplant 3. Known HIV infection 4. Women who are pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>PBC</keyword>
</DOC>